Cardinal Health (NYSE: CAH) Beats EPS Estimates Despite Q3 Revenue Miss

Cardinal Health shares fell 4.90% to $192.88 on Thursday despite posting a Q3 EPS beat, signaling investor disappointment over flat revenue performance and uncertainty around full-year guidance. The pharmaceutical distributor's earnings-per-share result exceeded consensus, though the company's top-line disappointment and cautious forward outlook overshadowed the positive bottom-line surprise.

Q3 2026 At a Glance

• EPS beat consensus on strong cost management, though exact figures were not disclosed
• Revenue missed estimates, marking a key negative for the quarter
• 2026 EPS guidance raised despite revenue headwinds, reflecting margin expansion confidence
• Net profit margin of 0.68% shows razor-thin profitability typical of pharmaceutical distribution

What Drove the Results

Cardinal Health's Q3 performance was split between a stronger-than-expected bottom line and a weaker-than-expected top line. The company's operating margin of 1.23% and gross margin of 3.69% underscore the capital-intensive, low-margin nature of healthcare distribution. Management's decision to raise full-year EPS guidance despite the revenue shortfall suggests confidence in operational efficiency gains and cost discipline, though the company faces ongoing pressure in a competitive distribution landscape.

The 19.4% earnings growth year-over-year provides some reassurance, but it arrives against a backdrop of slowing revenue expansion at 18.8%, indicating the company is squeezing margins rather than driving organic top-line momentum. For investors, this dynamic signals that Cardinal Health's near-term profitability may depend more on cost controls than business expansion.

Wall Street View

The stock's 4.9% decline despite the EPS beat suggests Wall Street is pricing in near-term uncertainty. With a trailing P/E of 27.71x and a forward P/E of 16.65x, Cardinal Health trades at a significant premium to its fundamentals, which may leave limited room for positive surprises. Analyst sentiment likely reflects caution around the revenue miss and macro uncertainty affecting pharmaceutical demand.

Investor Takeaway

Cardinal Health investors are facing a classic earnings-beat-but-miss scenario: the company delivered on the bottom line but fell short on the top line, which typically triggers profit-taking. While management's EPS guidance raise is encouraging, it comes with a caveat—growth is being engineered through margin expansion rather than revenue acceleration. For value-oriented investors, the high trailing P/E of 27.71x relative to slim 0.68% profit margins presents execution risk. Hold for existing positions, but new entry points may emerge if the stock stabilizes below $190.